Pfizer has 519 injectable products listed in the report, with 249, or 48 percent, labeled as available. The report says the supply of 152 are depleted and 118 are in limited supply.
The document does not include a reason for why an injectable is in shortage or out or stock.
In July, a tornado struck a Pfizer manufacturing plant and warehouse in Rocky Mount, N.C., which supplied 8 percent of the nation’s injectable drugs used in hospitals. The damage was mainly on the site’s storage side, but the company placed order limits on a dozen drugs as 65 solutions face worsened or new supply issues.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.